Notes
Ce contenu est réservé aux abonnés
Bibliographie
- Courtney, C. et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363, 2105–2115 (2004).
- Schneider, L. S. AD2000: donepezil in Alzheimer's disease. The Lancet 363, 2100–2101 (2004).
- Small, G. W., Kaufer, D., Mendiondo, M. S., Quarg, P. & Spiegel, R. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. International Journal of Clinical Practice 59, 473–477 (2005).
- Grossberg, G. Rivastigmine in Alzheimer Disease: Efficacy Over Two Years. American Journal of Geriatric Psychiatry 12, 420–431 (2004).
- Raskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P. & Damaraju, C. V. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch. Neurol. 61, 252–256 (2004).
- Howard, R. et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 366, 893–903 (2012).
- Prescrire en questions : anticholinestérasiques dans la maladie d'Alzheimer : que penser de l'essai dit Domino ? Rev Prescrire 2014 ; 34 (366) : 315-316.
- Howard, R. et al. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. The Lancet Neurology 14, 1171–1181 (2015).
- Herrmann, N. et al. A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease. Journal of the American Medical Directors Association 17, 142–147 (2016).
- Blanco-Silvente, L. et al. Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients. Int. J. Neuropsychopharmacol. 20, 519–528 (2017).
- Renn, B. N. et al. A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia. Am J Geriatr Psychiatry (2017).
- Wattmo, C., Londos, E. & Minthon, L. Longitudinal Associations between Survival in Alzheimer's Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services. Dement Geriatr Cogn Disord 40, 297–310 (2015).
- Wattmo, C., Londos, E. & Minthon, L. Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer’s disease: a prospective, observational study of factors affecting survival time from admission to death. BMC Neurol 1–11 (2016).
Fichiers
-
Fichier du cours pdf
